European Society of Cardiology (ESC) Congress 2022

First ESC Guidelines on managing cardiac toxicity related to cancer treatments

Roshini Claire Anthony, 20221109180001

The inaugural European Society of Cardiology (ESC) Guideline on cardio-oncology, revealed at the ESC Congress 2022 in Barcelona, Spain, provides some much-needed information on the concurrent management of cancer and cardiovascular (CV) disease.

Prophylactic anticoagulation in critical COVID-19: Is full-dose or standard-dose preferred?

Roshini Claire Anthony, 20221023100001

A full-dose prophylactic anticoagulation strategy reduced the risk of thrombosis in critically ill patients with COVID-19 who required intensive care unit (ICU)-level care compared with a standard-dose strategy, according to results of the COVID-PACT trial.

Dapagliflozin DELIVERs across full HF spectrum regardless of LVEF

Elvira Manzano, 20221004000000

The selective, oral sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF or HFpEF) in the phase III DELIVER* trial, touted as the largest and most inclusive thus far in this patient group.

Antihypertensive dosing TIME does not affect CV outcomes

Roshini Claire Anthony, 20220926150001

Timing of antihypertensive medication intake, be it in the morning or evening, does not appear to affect the risk of cardiovascular death or hospitalization for non-fatal myocardial infarction (MI) or non-fatal stroke, according to results of the TIME trial presented at ESC 2022.

P2Y12 monotherapy wins against aspirin for secondary prevention of CAD

Elaine Soliven, 20220924000000

Compared with aspirin alone, treatment with a P2Y₁₂ inhibitor (clopidogrel or ticagrelor) is associated with lower risks of cardiovascular (CV) death, myocardial infarction (MI), or stroke in patients with established coronary artery disease (CAD), according to the PANTHER* trial presented at ESC 2022.

DANFLU-1: High-dose quadrivalent flu vax reduces hospitalization, death in older adults

Roshini Claire Anthony, 20220922180001

Older adults who receive a high-dose quadrivalent influenza vaccine have a 49 percent reduced risk of death and a 64 percent reduced risk of hospitalization for influenza or pneumonia compared with those who receive a standard-dose vaccine, results of the DANFLU-1 study showed.

Evolocumab benefits build up in FOURIER OLE

Elvira Manzano, 20220919000000

Early, long-term lipid lowering with the PCSK9 inhibitor evolocumab further reduces cardiovascular (CV) events, including CV death, without any safety signal, in the FOURIER* open-label extension (OLE) study.

Phase II data reveal treatment potential of pegozafermin for severe hypertriglyceridaemia

Audrey Abella, 20220914100000

The phase II ENTRIGUE trial presented at ESC 2022 showed the potential of pegozafermin to improve triglyceride levels and other lipid-related metrics in individuals with severe hypertriglyceridaemia.

Asundexian + DAPT a treatment alternative for acute MI?

Audrey Abella, 20220913100000

Adding the oral factor XIa (FXIa) inhibitor asundexian to dual antiplatelet therapy (DAPT) may be a safe and effective oral anticoagulation (OAC) alternative for acute MI patients, findings from the PACIFIC-AMI study suggest.

Polypill strategy triumphs in reducing MACE post-MI

Roshini Claire Anthony, 20220912140001

A polypill comprising aspirin, ramipril, and atorvastatin, significantly reduced the incidence of major adverse cardiovascular (CV) events in patents with a recent myocardial infarction (MI), according to results of a phase III trial presented at ESC 2022.